Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Jul 2001 07:07 AM
RNS
Corporate Action
13 Jul 2001 07:00 AM
RNS
Proposed Placing & Open Offer
13 Jul 2001 07:00 AM
RNS
Preliminary Results
29 Jun 2001 04:43 PM
RNS
Statement re Suspension
20 Jun 2001 07:00 AM
RNS
Additional Funding
25 Apr 2001 10:31 AM
RNS
Additional Funding
27 Mar 2001 07:00 AM
RNS
Funding to Support Expansion
31 Oct 2000 07:00 AM
RNS
Second Interim Results 2000
12 Jul 2000 02:24 PM
RNS
Interim Statement
19 Apr 2000 05:10 PM
RNS
Result of Open Offer
18 Apr 2000 05:48 PM
RNS
Result of EGM
18 Apr 2000 11:05 AM
RNS
Result of EGM
27 Mar 2000 07:01 AM
RNS
Restoration of Trading on AIM
24 Mar 2000 04:26 PM
RNS
Statement re Restoration of Dealing
24 Mar 2000 08:47 AM
RNS
Entitlement Details
24 Mar 2000 08:46 AM
RNS
Proposed Acquisition and Placing and Open Offer
17 Feb 2000 01:56 PM
RNS
Statement re Suspension of Trading
18 Jan 2000 03:55 PM
RNS
Statement re Share Price Movement
26 Nov 1999 02:31 PM
RNS
Insinger Townsley Appointed as Nominated Broker

mmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

UK 100

Latest directors dealings